Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio SciencesPR Newswire • 18 days ago
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences PR Newswire...
Share to Feed
Company presentation and fireside chat on April 11th at 11:45 a.m. ETCAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology...
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader...
In trading on Monday, shares of Foghorn Therapeutics Inc (FHTX) crossed below their 200 day moving average of 6.07, changing hands as low as 5.85 per share. Foghorn Therapeutics Inc shares...
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative...
We note that the Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) Chief Strategy & Business Operations Officer, Fanny Cavalie...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 FHD-909, a first-in-class BRM selective inhibitor, selected for...
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024 Oral...